AIMS/HYPOTHESIS: Exercise training improves glycaemic control in some but not all individuals and little research has been done regarding genetic impact on the exercise training response in type 2 diabetes. The purpose of this study was to investigate the influence of the Pro(12)Ala variant of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on changes in fasting plasma glucose in response to exercise training. METHODS: The study population comprised 139 sedentary type 2 diabetic patients (age: 54.4+/-7.2; HbA(1)c: 7.7+/-0.9%) who completed 3 months ofsupervised exercise training. The primary outcome variable in our analysis was the post-intervention change in blood glucose. Other assessments included measures of body composition, insulin sensitivity indices and maximal oxygen uptake (VO(2max)). RESULTS: The frequency of the Ala allele was 8.3% and the genotypes were in Hardy-Weinberg equilibrium. At baseline, neither body composition variables (weight, BMI, waist circumference), glucose homeostasis variables (glucose, insulin, HbA(1)c, homeostasis model assessment method) nor VO(2max) were different between genotypes (wild-type: Pro(12)Pro n=117, Ala carriers: X(12)Ala n=22). The exercise-training intervention led to similar improvements in body composition and glucose homeostasis variables in both genotype groups (p<0.05). The change in fasting plasma glucose was significantly different between PPARgamma2 genotypes (-1.66 mmol/l vs -0.54 mmol/l, Ala carriers and wild-type, respectively) (p=0.034 unadjusted and p=0.089 including baseline glucose) and the significant association between genotype and glucose response remained after adjusting for statistically significant predictors (age, changes in insulin and BMI [p=0.015]) and including baseline glucose, insulin and BMI (p=0.031). CONCLUSIONS/ INTERPRETATION: These data suggest that the Pro(12)Ala polymorphism may influence the glycaemic response to exercise in type 2 diabetes.
RCT Entities:
AIMS/HYPOTHESIS: Exercise training improves glycaemic control in some but not all individuals and little research has been done regarding genetic impact on the exercise training response in type 2 diabetes. The purpose of this study was to investigate the influence of the Pro(12)Ala variant of the peroxisome proliferator-activated receptor (PPAR) gamma2 gene on changes in fasting plasma glucose in response to exercise training. METHODS: The study population comprised 139 sedentary type 2 diabeticpatients (age: 54.4+/-7.2; HbA(1)c: 7.7+/-0.9%) who completed 3 months of supervised exercise training. The primary outcome variable in our analysis was the post-intervention change in blood glucose. Other assessments included measures of body composition, insulin sensitivity indices and maximal oxygen uptake (VO(2max)). RESULTS: The frequency of the Ala allele was 8.3% and the genotypes were in Hardy-Weinberg equilibrium. At baseline, neither body composition variables (weight, BMI, waist circumference), glucose homeostasis variables (glucose, insulin, HbA(1)c, homeostasis model assessment method) nor VO(2max) were different between genotypes (wild-type: Pro(12)Pro n=117, Ala carriers: X(12)Ala n=22). The exercise-training intervention led to similar improvements in body composition and glucose homeostasis variables in both genotype groups (p<0.05). The change in fasting plasma glucose was significantly different between PPARgamma2 genotypes (-1.66 mmol/l vs -0.54 mmol/l, Ala carriers and wild-type, respectively) (p=0.034 unadjusted and p=0.089 including baseline glucose) and the significant association between genotype and glucose response remained after adjusting for statistically significant predictors (age, changes in insulin and BMI [p=0.015]) and including baseline glucose, insulin and BMI (p=0.031). CONCLUSIONS/ INTERPRETATION: These data suggest that the Pro(12)Ala polymorphism may influence the glycaemic response to exercise in type 2 diabetes.
Authors: A Meirhaeghe; L Fajas; N Helbecque; D Cottel; P Lebel; J Dallongeville; S Deeb; J Auwerx; P Amouyel Journal: Hum Mol Genet Date: 1998-03 Impact factor: 6.150
Authors: J A Douglas; M R Erdos; R M Watanabe; A Braun; C L Johnston; P Oeth; K L Mohlke; T T Valle; C Ehnholm; T A Buchanan; R N Bergman; F S Collins; M Boehnke; J Tuomilehto Journal: Diabetes Date: 2001-04 Impact factor: 9.461
Authors: P W Franks; J Luan; P O Browne; A-H Harding; S O'Rahilly; V K K Chatterjee; N J Wareham Journal: Metabolism Date: 2004-01 Impact factor: 8.694
Authors: E Bonora; S Kiechl; J Willeit; F Oberhollenzer; G Egger; G Targher; M Alberiche; R C Bonadonna; M Muggeo Journal: Diabetes Date: 1998-10 Impact factor: 9.461
Authors: S-M Ruchat; T Rankinen; S J Weisnagel; T Rice; D C Rao; R N Bergman; C Bouchard; L Pérusse Journal: Diabetologia Date: 2009-12-31 Impact factor: 10.122
Authors: Thomas Yates; Melanie J Davies; Joseph Henson; Charlotte Edwardson; David Webb; Danielle H Bodicoat; M'Balu Webb; Philip Howard; Jackie A Cooper; Steve E Humphries; Kamlesh Khunti; Philippa Talmud Journal: PLoS One Date: 2015-05-14 Impact factor: 3.240
Authors: José Maria Costa-Júnior; Sandra Mara Ferreira; Mirian Ayumi Kurauti; Diana L Bernstein; Elena G Ruano; Vasumathi Kameswaran; Jonathan Schug; Ricardo Freitas-Dias; Claudio C Zoppi; Antonio C Boschero; Camila A M de Oliveira; Gustavo J Santos; Everardo M Carneiro; Klaus H Kaestner Journal: Int J Mol Sci Date: 2021-12-21 Impact factor: 5.923
Authors: Miroslav Petr; Petr Stastny; Adam Zajac; James J Tufano; Agnieszka Maciejewska-Skrendo Journal: Int J Mol Sci Date: 2018-05-15 Impact factor: 5.923